Study shows how amyloid aggregates alter brain cells in Alzheimer’s disease

Researchers from CNRS and the Université de Bordeaux have revealed the mechanism through which amyloid peptide aggregates alter brain cells to cause the harmful effects seen in Alzheimer’s disease.

Image Credit: sfam_photo / Shutterstock

As described in the journal Cell Reports, the aggregates alter the normal function of connections between neurons by interacting with a key enzyme of synaptic plasticity.

Alzheimer’s disease is characterized by neuronal loss, fibrillar degeneration and the accumulation of amyloid peptides that form on amyloid plaques, but the involvement of these disease features in the development of symptoms has been unclear.

For example, researchers know that amyloid peptides impair synapses, but how they do this has been poorly understood.

Now, a study conducted by Daniel Choquet and colleagues has shown in animal models of Alzheimer’s that peptide oligomers interact with a key enzyme in synaptic balance and prevent its normal mobilization.

The enzyme, called CamKII, usually orchestrates synaptic plasticity, which enables nerve cells to reinforce their responses to the signals they exchange.

Groups of neurons involved in memorizing information are connected by synapses, which are controlled by mechanisms of synaptic plasticity. Synaptic plasticity is key to memory and the ability to learn.

When the connection between two neurons needs to be reinforced so that information can be memorized, CamKII is activated. This leads to a series of reactions that enhance the transmission of messages between the neurons.

Amyloid peptides stop CamKII from contributing to this synaptic plasticity process, which eventually leads to loss of the synapse.

The discovery could be used to help understand the early stages of Alzheimer’s disease, when the cognitive deficiencies first start to appear.

Next, researchers plan to continue studying amyloid aggregates and try to prevent their interaction with CamKII that causes the loss of synapses seen in this disease.

Source:

https://www.alphagalileo.org/en-gb/Item-Display/ItemId/164757?returnurl=https://www.alphagalileo.org/en-gb/Item-Display/ItemId/164757

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 20). Study shows how amyloid aggregates alter brain cells in Alzheimer’s disease. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/20180612/Study-shows-how-amyloid-aggregates-alter-brain-cells-in-Alzheimers.aspx.

  • MLA

    Robertson, Sally. "Study shows how amyloid aggregates alter brain cells in Alzheimer’s disease". News-Medical. 22 December 2024. <https://www.news-medical.net/news/20180612/Study-shows-how-amyloid-aggregates-alter-brain-cells-in-Alzheimers.aspx>.

  • Chicago

    Robertson, Sally. "Study shows how amyloid aggregates alter brain cells in Alzheimer’s disease". News-Medical. https://www.news-medical.net/news/20180612/Study-shows-how-amyloid-aggregates-alter-brain-cells-in-Alzheimers.aspx. (accessed December 22, 2024).

  • Harvard

    Robertson, Sally. 2019. Study shows how amyloid aggregates alter brain cells in Alzheimer’s disease. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/20180612/Study-shows-how-amyloid-aggregates-alter-brain-cells-in-Alzheimers.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
£1M funding boost for new project to trial Parkinson’s treatments on digital twin brain